BRIEF—Arecor inks new deal with big pharma partner

UK biopharma Arecor Therapeutics has entered into an agreement with an unnamed ‘leading biopharmaceutical company’ to support the ongoing development of a biosimilar product.

This revenue-generating collaboration follows an earlier technology partnership between the two companies, utilizing Arecor’s proprietary technology platform, Arestat, and formulation expertise.

Sarah Howell, chief executive of Arecor, said: “This collaboration demonstrates the strength of our know-how and expertise and the value that expertise can bring to our partners’ research programs. We’re delighted to be working again with an existing partner, strengthening a key relationship and building on our track record of partnerships with leading biopharmaceutical and biotechnology companies.”